Unlocking potent anti-tuberculosis natural products through structure-activity relationship analysis.

Journal: Natural products and bioprospecting
Published Date:

Abstract

Tuberculosis (TB) remains a world health problem due to the high number of affected individuals, high mortality rates, prolonged treatment durations, and the increasing prevalence of resistance to commercial TB drugs. The emergence of resistance to anti-TB drugs has necessitated urgent research into drug discovery and development, focusing on novel mechanisms of action against Mycobacterium tuberculosis resistant strains. Natural products, with their remarkable structural diversity and bioactivity, are promising sources for the development of new TB drugs or the identification of potential chemical scaffolds exhibiting potent and novel biological activity with minimal or no cytotoxicity to host cells. This review focuses on potent anti-TB natural products with minimum inhibitory concentration (MIC) values below 5 µg mL and examines their structure-activity relationship (SAR). Significant characteristics and relevant biological properties of each compound were analysed using a Random Forest, machine learning algorithm, to explore SAR. Using molecular docking, AutoDock Vina was utilised to assess molecular interactions with protein targets, and predictive accuracy was enhanced using the XGBoost machine learning model. These analyses provide insights into the mode of action of these compounds and help identify key structural features contributing to their anti-TB activity. In addition, this review examines the correlation between the potency of selected anti-TB compounds and their cytotoxicity, offering valuable insights for the identification of promising scaffolds in TB drug discovery.

Authors

  • Delfly Booby Abdjul
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia. booby_abdjul@yahoo.com.
  • Fitri Budiyanto
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia.
  • Joko Tri Wibowo
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia.
  • Tutik Murniasih
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia.
  • Siti Irma Rahmawati
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia.
  • Dwi Wahyu Indriani
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia.
  • Masteria Yunovilsa Putra
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia.
  • Asep Bayu
    Research Center for Vaccine and Drugs, Research Organization for Health, National Research and Innovation Agency (BRIN), Jalan Raya Jakarta Bogor KM.46, Cibinong, Bogor, West Java, 16911, Indonesia. asep044@brin.go.id.

Keywords

No keywords available for this article.